Glaukos (GKOS) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed Insulet (PODD) over the past year, gaining 104.8% versus a loss of 57.1%. Over five years, GKOS leads with a +284.2% price change compared with -55.3% for PODD. Glaukos is the larger company by market cap ($10.16 billion vs $9.32 billion), about 1.1 times the size.
On valuation, Insulet trades at a lower forward P/E (17.4x vs 328.9x for Glaukos). Insulet converts more of its revenue into profit, with a net margin of 9.1% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | PODD |
|---|---|---|
| Share price | $172.18 | $134.36 |
| Market cap | $10.16B | $9.32B |
| 1-day change | +6.55% | -0.27% |
| YTD return | +52.49% | -52.73% |
| 1-year return | +104.76% | -57.14% |
| 5-year return | +284.16% | -55.29% |
| P/E ratio (TTM) | — | 25.21 |
| Forward P/E | 328.86 | 17.38 |
| EPS (TTM) | $-3.26 | $5.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $2.71B |
| Revenue growth (YoY) | +32.33% | +30.73% |
| Net income (latest FY) | $-187.69M | $247.10M |
| Gross margin | 55.72% | 71.63% |
| Operating margin | -39.33% | 17.50% |
| Net margin | -36.99% | 9.12% |
| 52-week high | $191.62 | $354.88 |
| 52-week low | $73.16 | $126.40 |
| Distance from 52-week high | -10.15% | -62.14% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +15.40% | +27.24% |
| Average volume | 791.91K | 1.69M |
| Shares outstanding | 58.98M | 69.35M |
| Employees | 1,094 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GKOS has outperformed PODD by 161.9 percentage points over the past year.
- Insulet is more profitable, keeping 9.1 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
GKOS vs PODD FAQ
Which is bigger, Glaukos or Insulet?
Glaukos (GKOS) is larger, with a market capitalization of $10.16B compared with $9.32B for Insulet (PODD).
Which stock has performed better over the past year, GKOS or PODD?
GKOS returned +104.76% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Are Glaukos and Insulet in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.